Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Fig. 2

Bubble charts of the cumulative incidence by different (A) median treatment duration and (B) the proportion of CHB patients with preexisting cirrhosis subgroups. Trend lines fitted linearly represent the predicted HCC incidence according to different treatments. ETV, Entecavir; TDF, Tenofovir disoproxil fumarate; Other NAs, Nucleos(t)ide Analogues other than ETV and TDF (including Lamivudine, Telbivudine and Adefovir). The bubble size represents the sample size for each study

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us